TGFB1 and renal fibrosis: Liraglutide, for example, a GLP-1 analog with a longer half-life, can attenuate UUO-induced renal fibrosis through activation of GLP-1 receptor (GLP-1R) and activation of TGF-β1/Smad3 and extracellular signal-regulated kinases (ERK) 1/2 signaling pathways, thereby decreasing extracellular matrix secretion and deposition (Li et al., 2018).